--- title: "Assenagon Asset Management S.A. Grows Position in Teva Pharmaceutical Industries Ltd. $TEVA" type: "News" locale: "en" url: "https://longbridge.com/en/news/295294334.md" description: "Assenagon Asset Management increased its stake in Teva Pharmaceutical by 128.1% in Q2, holding over 3 million shares valued at $103.5 million. Other institutions like Legal & General and TD Asset Management also boosted holdings. Meanwhile, EVP Eliyahu Sharon Kalif sold shares. Analysts upgraded ratings and raised price targets, with an average 'Moderate Buy' rating and $42 target. Teva recently reported Q1 EPS of $0.02 on $4.14 billion revenue." datetime: "2026-08-08T07:28:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295294334.md) - [en](https://longbridge.com/en/news/295294334.md) - [zh-HK](https://longbridge.com/zh-HK/news/295294334.md) generator: "portal-rs" --- # Assenagon Asset Management S.A. Grows Position in Teva Pharmaceutical Industries Ltd. $TEVA Assenagon Asset Management S.A. lifted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 128.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 3,056,017 shares of the company's stock after purchasing an additional 1,716,315 shares during the period. Assenagon Asset Management S.A. owned about 0.27% of Teva Pharmaceutical Industries worth $103,538,000 at the end of the most recent quarter. - MarketBeat Week in Review – 02/03 - 02/07 Several other institutional investors also recently bought and sold shares of the business. Legal & General Group Plc boosted its holdings in Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company's stock worth $112,618,000 after acquiring an additional 228,189 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 8.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company's stock valued at $33,506,000 after acquiring an additional 80,106 shares in the last quarter. Norges Bank purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $1,098,060,000. TD Asset Management Inc raised its position in shares of Teva Pharmaceutical Industries by 47.1% in the 4th quarter. TD Asset Management Inc now owns 369,023 shares of the company's stock valued at $11,517,000 after purchasing an additional 118,075 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter worth approximately $9,126,000. 54.05% of the stock is owned by hedge funds and other institutional investors. ## Insider Buying and Selling In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the transaction, the executive vice president directly owned 172,184 shares in the company, valued at approximately $6,131,472.24. This represents a 47.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.54% of the company's stock. ## Analyst Ratings Changes - Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now A number of research analysts have issued reports on the stock. Weiss Ratings raised shares of Teva Pharmaceutical Industries from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, July 31st. Barclays upped their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an "overweight" rating in a research report on Wednesday, May 6th. UBS Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an "overweight" rating in a research note on Thursday, April 30th. Finally, Truist Financial increased their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $42.00. **Get Our Latest Report on TEVA** ## Teva Pharmaceutical Industries Trading Up 1.4% - 2 Generic Drug Stocks Ready to Surge in 2025 Shares of TEVA stock opened at $35.30 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries Ltd. has a twelve month low of $16.08 and a twelve month high of $37.35. The company's 50-day moving average price is $33.25 and its 200-day moving average price is $32.82. The stock has a market cap of $40.59 billion, a price-to-earnings ratio of 58.83, a PEG ratio of 3.72 and a beta of 0.86. Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. As a group, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.96 earnings per share for the current year. ## Teva Pharmaceutical Industries Profile (Free Report) Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries. Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease. ## See Also - Five stocks we like better than Teva Pharmaceutical Industries - Datadog’s Drop Says More About Expectations Than Earnings - D-Wave's Quantum Breakthrough Couldn't Save QBTS From a Sell-Off - Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus - Solventum Nears Inflection Point As It Begins to Unlock Value **Want to see what other hedge funds are holding TEVA?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now? Before you consider Teva Pharmaceutical Industries, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list. While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md) - [LGEN.UK](https://longbridge.com/en/quote/LGEN.UK.md) - [MUFG.US](https://longbridge.com/en/quote/MUFG.US.md) - [8306.JP](https://longbridge.com/en/quote/8306.JP.md) - [TD.US](https://longbridge.com/en/quote/TD.US.md) - [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md) - [BCS.US](https://longbridge.com/en/quote/BCS.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [TFC.US](https://longbridge.com/en/quote/TFC.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review](https://longbridge.com/en/news/296355997.md) - [Pacer Advisors Inc. Sells 484,736 Shares of Teva Pharmaceutical Industries Ltd. $TEVA](https://longbridge.com/en/news/295637382.md) - [Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?](https://longbridge.com/en/news/296006711.md) - [Teva EVP Business Development Evan Lippman sells 18,600 shares for $680,291.28](https://longbridge.com/en/news/296394259.md) - [Aurinia settles Teva patent suit, sets generic voclosporin launch no earlier than Dec. 7, 2036](https://longbridge.com/en/news/296394736.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**